AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed ...

Investing.com -- Daiichi Sankyo Co., Ltd. (TSE:TYO: 4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a ...

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09 trial, when used as a ...